Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM5 | P08912 | 2/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CHKA | P35790 | 1/20 | 0.37 |
| ▸ | KDM5C | P41229 | 1/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL306395 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL29299554 | 1.00 | CHRM5 (0.50) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL27229072 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL5550813 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL5239633 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| Hydrochloric Acid SCHEMBL28968883 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL8038178 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL6537424 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL10567168 | 0.98 | CHRM5 (0.48) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 | |
| SCHEMBL337070 | 0.98 | HSD17B10 (0.52) | CHRM5CHRM3HSD17B10SIGMAR1SLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 549 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098441-A1 | COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES | SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-05-15 | — | — | WO | claimed |
| US-20260108639-A1 | COMPLEX FOR DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS, USE, AND CONTRAST AGENT THEREOF | NATIONAL ATOMIC RES INSTITUTE (TW) | 2026-04-23 | — | — | US | claimed |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | UNIV JOHNS HOPKINS (US) | 2026-04-23 | — | — | US | claimed |
| EP-4724061-A2 | PRODRUGS FOR COMPOUNDS SPECIFIC TO GRANZYME B AND USES THEREOF | Cytosite Biopharma Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4719494-A2 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | The Johns Hopkins University (US) | 2026-04-08 | — | — | EP | claimed |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CHENGDU SHETAI MEDICAL TECHNOLOGY CO., LTD. (CN) | 2026-03-12 | — | — | US | claimed |
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | UNIV JOHNS HOPKINS (US) | 2025-11-06 | — | — | US | claimed |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2025-10-21 | — | — | US | claimed |
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2025-08-21 | — | — | US | claimed |
| EP-4590346-A1 | FIBROBLAST ACTIVATION PROTEIN (FAP) INHIBITORS, FAP CONJUGATES, AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | Nuclidium AG (CH) | 2025-07-30 | — | — | EP | claimed |
| US-20180126012-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2018-05-10 | — | — | US | claimed |
| EP-3279197-A1 | DIAGNOSIS, TREATMENT AND PREVENTION OF NEUROTENSIN RECEPTOR-RELATED CONDITIONS | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2018-02-07 | — | — | EP | claimed |
| WO-2018022125-A1 | RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2018-02-01 | — | — | WO | claimed |
| US-20180021461-A1 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2018-01-25 | — | — | US | claimed |
| US-20180022768-A1 | RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2018-01-25 | — | — | US | claimed |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2017-05-11 | — | — | US | claimed |
| WO-2016182804-A1 | RADIOLIGANDS FOR PRETARGETED PET IMAGING AND METHODS OF THEIR THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2016-11-17 | — | — | WO | claimed |
| US-20160208021-A1 | Molecular constructs with targeting and effector moieties | Immunwork Inc. (TW) | 2016-07-21 | — | — | US | claimed |
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | claimed |
| US-5876698-A | Macrocyclic polymer complexing agents, their complexes, process for their production and pharmaceutical agents containing these compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-03-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250340701-A1 | DENDRIMER-DELIVERED ALPHA-PARTICLE RADIOTHERAPY FOR TREATMENT OF GLIOBLASTOMA AND OTHER CANCERS IN THE BRAIN | TUBA3E, TUBB2A, ADCYAP1R1 | CHRM5 2059/4885CHRM3 3771/4885HSD17B10 4355/4885 |
| US-20250262335-A1 | PSMA-Targeting Ligands with Optimal Properties for Imaging and Therapy | PSMA1, PSMA2, FOLH1 | CHRM5 3396/4885CHRM3 2559/4885HSD17B10 4215/4885 |
| US-20180021461-A1 | TARGETED RADIOTHERAPY CHELATES FOR IN SITU IMMUNE MODULATED CANCER VACCINATION | CD47, STING1, ARG1 | CHRM5 993/4885CHRM3 590/4885HSD17B10 4767/4885 |
| US-20170128572-A1 | LONG-LIVED GADOLINIUM BASED TUMOR TARGETED IMAGING AND THERAPY AGENTS | H1-3, H1-2, H1-4 | CHRM5 94/4885CHRM3 100/4885HSD17B10 2477/4885 |
| US-20260108637-A1 | USES OF PSMA-TARGETING AND TSPO-TARGETING COMPOUNDS FOR EVALUATION OF INJURIES IN THE PERIPHERAL NERVOUS SYSTEM | MUSK, TNNC1, TNNI3 | CHRM5 809/4885CHRM3 155/4885HSD17B10 4069/4885 |
| US-20160208021-A1 | Molecular constructs with targeting and effector moieties | CD2BP2, HAVCR2, DCLRE1B | CHRM5 4504/4885CHRM3 4162/4885HSD17B10 4149/4885 |
| US-20260069728-A1 | MULTI-TARGETING COMPOUND AND USE THEREOF | CXCR4, CXCR2, GRPR | CHRM5 828/4885CHRM3 394/4885HSD17B10 4483/4885 |
| US-12447217-B2 | Fibroblast activation protein (FAP) inhibitors, FAP conjugates, and diagnostic and therapeutic uses thereof | FAP, FIBP, FGFR1 | CHRM5 4871/4885CHRM3 4869/4885HSD17B10 3879/4885 |
| US-20260108639-A1 | COMPLEX FOR DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS, USE, AND CONTRAST AGENT THEREOF | ASGR1, FABP1, FFAR1 | CHRM5 2315/4885CHRM3 1581/4885HSD17B10 1271/4885 |
| US-20180022768-A1 | RADIOACTIVE PHOSPHOLIPID METAL CHELATES FOR CANCER IMAGING AND THERAPY | PHOSPHO1, H1-3, H1-0 | CHRM5 213/4885CHRM3 186/4885HSD17B10 2752/4885 |
| US-20180126012-A1 | Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies | CD274, CD47, PDCD1 | CHRM5 2890/4885CHRM3 2136/4885HSD17B10 4384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.